Oklahoma Healthcare Wire: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

March 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

April 2026

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Press releases published on April 28, 2026

4 hours ago

Narconon Marks 60 Years of Proven Results Creating Drug-Free Lives at Oklahoma Conference

EIN Presswire

an hour ago

Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer

GlobeNewswire

an hour ago

Reacta Healthcare Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board

GlobeNewswire

3 hours ago

Castle Rock Hormone Health Announces National Franchise Launch with Franchise Sidekick Amid Growing Demand for Longevity Medicine

GlobeNewswire

3 hours ago

Bioxodes to present final Phase 2a trial results confirming breakthrough potential of BIOX-101 for intracerebral hemorrhage in poster at ESOC 2026

GlobeNewswire

3 hours ago

Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

GlobeNewswire

3 hours ago

Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial

GlobeNewswire

3 hours ago

Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study

GlobeNewswire

4 hours ago

Santhera gibt positive Entscheidung des AIFA-Vorstands zur Erstattung von AGAMREE® (Vamorolon) in Italien bekannt

GlobeNewswire

4 hours ago

Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy

GlobeNewswire

4 hours ago

Santhera Pharmaceuticals Jahresergebnisse für das am 31. Dezember 2025 endende Geschäftsjahr

GlobeNewswire

4 hours ago

Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025

GlobeNewswire

5 hours ago

CORE Soft Tissue Therapy Reports Full Booking Capacity in First Year as Referral Growth Supports South London Expansion

GlobeNewswire

6 hours ago

Rapid Nutrition PLC Announces FY2025 Results and 2026 Strategic Outlook

GlobeNewswire